ONWARD Medical Launches a New ADR Program
Recently, ONWARD Medical N.V. made an exciting move by establishing a sponsored Level 1 American Depositary Receipt (ADR) program in the United States. This program aims to facilitate trading for U.S. investors and has commenced trading on the OTCQX Best Market using the ticker symbol ONWRY. The initiative coincides with positive developments in the company’s innovative spinal cord stimulation therapies that seek to restore movement and independence in individuals suffering from spinal cord injuries and movement disabilities.
Importance of the ADR Program
By creating the ADR program in partnership with the Bank of New York Mellon (BNY), ONWARD Medical hopes to attract U.S. institutional investors who prefer transactions in dollars and in securities traded in the U.S. market. According to CEO Dave Marver, this initiative is a strategic step that simplifies access for both institutional and retail investors, enhancing their engagement with the company's growth story.
Anticipated Benefits of the OTCQX Upgrade
The shift to the OTCQX Market is more than just a trading venue; it represents a significant milestone for ONWARD Medical. It symbolizes enhanced visibility among U.S. investors and aims to broaden the company's shareholder base. With its new ADRs, investors can easily purchase, hold, and sell shares, addressing the needs of a demographic eager for investment opportunities in the field of biomedicine.
Company's Commitment to Innovation
ONWARD Medical, based in the Netherlands, has a rich history of innovation in medical technology, particularly in spinal cord therapy solutions. The company is recognized for its groundbreaking ARC Therapy, which has received multiple Breakthrough Device Designations from the U.S. Food and Drug Administration (FDA). Their ARC-EX system, which is currently cleared for sale, represents a significant step in developing non-invasive therapies aimed at restoring functionality in patients with spinal cord injuries.
Looking Ahead: Products and Research
The company isn't resting on its past achievements. ONWARD Medical is actively developing new technologies, including the investigational ARC-IM system, which may incorporate a brain-computer interface (BCI) to enhance rehabilitation efforts further. This forward-thinking approach is essential as it aligns the company with the rapid advancements in medical technologies, aiming to offer enhanced solutions for those with mobility challenges.
Global Expansion and Local Focus
Headquartered in the Netherlands, ONWARD Medical has extended its reach globally with operations in Switzerland and a significant presence in Boston, Massachusetts. This strategic positioning enables the company to bridge European innovations with U.S. market dynamics, fostering a robust network for growth opportunities.
Investor Resources and Transparency
U.S. investors are encouraged to keep abreast of ONWARD Medical's continual developments. Current financial disclosures and real-time quotes are accessible, making it easier for interested parties to track the company's performance. The available resources contribute to the transparency that investors expect in the rapidly evolving healthcare landscape.
About ONWARD Medical
ONWARD Medical is at the forefront of creating life-changing therapies aimed at helping individuals regain mobility and independence after spinal cord injuries. With a profound commitment to scientific research and clinical studies, the company combines innovative technology with practical applications in rehabilitation.
Frequently Asked Questions
What is the significance of ONWARD Medical's new ADR program?
The ADR program allows U.S. investors to trade ONWARD shares more conveniently in dollars, broadening investor access and increasing liquidity.
What therapies does ONWARD Medical offer?
ONWARD Medical focuses on spinal cord stimulation therapies, including the ARC Therapy system that aims to restore movement and function in patients with spinal cord injuries.
Where is ONWARD Medical headquartered?
ONWARD Medical is headquartered in the Netherlands, with additional offices in Switzerland and the United States, specifically in Boston, Massachusetts.
What regulatory approvals has ONWARD Medical received?
ONWARD Medical has received Breakthrough Device Designations from the FDA for its ARC Therapy systems, indicating its innovative approach and potential impact.
How does ONWARD Medical plan to expand its market presence?
The company plans to expand its market presence through its ADR program, which aims to enhance engagement with U.S. investors and broaden its shareholder base.
